You are here
Resection of colorectal liver metastases after second-line chemotherapy: is it worthwhile? A LiverMetSurvey analysis of 6415 patients
European Journal of Cancer, June 2017, Pages 7 - 15
Patient outcome after resection of colorectal liver metastases (CLM) following second-line preoperative chemotherapy (PCT) performed for insufficient response or toxicity of the first-line, is little known and has here been compared to the outcome following first-line.
Patients and methods
From January 2005 to June 2013, 5624 and 791 consecutive patients of a prospective international cohort received 1 and 2 PCT lines before CLM resection (group 1 and 2, respectively). Survival and prognostic factors were analysed.
After a mean follow-up of 30.1 months, there was no difference in survival from CLM diagnosis (median, 3-, and 5-year overall survival [OS]: 58.6 months, 76% and 49% in group 2 versus 58.9 months, 71% and 49% in group 1, respectively, P = 0.32). After hepatectomy, disease-free survival (DFS) was however shorter in group 2: 17.2 months, 27% and 15% versus 19.4 months, 32% and 23%, respectively (P = 0.001). Among the initially unresectable patients of group 1 and 2, no statistical difference in OS or DFS was observed. Independent predictors of worse OS in group 2 were positive primary lymph nodes, extrahepatic disease, tumour progression on second line, R2 resection and number of hepatectomies/year <50. Positive primary nodes, synchronous and bilateral metastases were predictors of shorter DFS. Initial unresectability did not impact OS or DFS in group 2.
CLM resection following second-line PCT, after oncosurgically favourable selection, could bring similar OS compared to what observed after first-line. For initially unresectable patients, OS or DFS is comparable between first- and second-line PCT. Surgery should not be denied after the failure of first-line chemotherapy.
- A heavier tumour burden was found in patients with colorectal liver metastases (CLM) resection after 2nd-line preoperative chemotherapy (PCT).
- The 49% 5-year overall survival (OS) from CLM diagnosis in this group was similar to that after 1st-line.
- OS or disease-free survival was comparable for the subsets of initially unresectable of two PCT groups.
- Surgery of CLM may be proposed to resect CLM ever after 2nd-line chemotherapy.
Keywords: Colorectal cancer, Liver metastasis, Preoperative chemotherapy, Second line, Hepatectomy.
a Hepatobiliary Center, AP-HP Hôpital Paul Brousse, Université Paris-Sud, Inserm U935, Villejuif, France
b Eastern Hepatobiliary Surgery Hospital/National Liver Cancer Center, Second Military Medical University, Shanghai, China
c Department of Oncology, AP-HP Hôpital Paul Brousse, Université Paris-Sud, Inserm U935, Villejuif, France
d Department of HPB Surgery and Transplantation, Curry Cabral Hospital, Lisbon, Portugal
e Department of Digestive Surgery, Hôpital Saint André, Bordeaux, France
f Hepatobiliary Surgery Unit, Agostino Gemelli Hospital, Catholic University of the Sacred Heart, Rome, Italy
g Department of HPB and Digestive Surgery, Ospedale Mauriziano Umberto I, Turin, Italy
h HPB Surgery and Transplantation Unit, Hôpital Saint-Luc, Centre Hospitalier de l'Université de Montréal, Montréal, Canada
i Department of Oncology and Digestive Surgery, CHU Amiens-Picardie, Amiens, France
j Hepatobiliary and Pancreatic Surgery Unit, Department of Surgery, Dr. Josep Trueta Hospital, IdlBGi, Girona, Spain
k Department of Transplantation and Liver Surgery, Helsinki University Hospital, Helsinki, Finland
l Unit of HPB Surgery, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
m Division of Colon & Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan
n School of Medicine, National Yang-Ming University, Taipei, Taiwan
o Department of Surgery, Medical University of Vienna, General Hospital, Vienna, Austria
p Department of Oncologic Surgery, Institut Gustave Roussy, Villejuif, France
q Research Center of Surgery, Russian Academy of Medical Science, Moscow, Russia
r Division of Surgery A, Department of Surgery, GB Rossi Hospital, University of Verona, Verona, Italy
∗ Corresponding author: Hepatobiliary Center, AP-HP Hôpital Paul Brousse, Université Paris-Sud, Inserm U935, 12 Avenue Paul Vaillant Couturier, 94804 Villejuif, France. Fax: +33 1 45 59 38 57.
1 These authors contributed equally to this work.
2 Current address: Cancer Chronotherapy Unit, Cancer Research Centre, Warwick Medical School, Warwick University, Coventry, Warwickshire, UK.
3 Current address: Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
© 2017 Elsevier Ltd, All rights reserved.